Welcome to the Lilly Interactive Pipeline!

Data Last Updated
July 15, 2012

Pipeline movement since January 17, 2012

Pipeline Overview

For information on
ongoing clinical
trials, please
click here

Please note: If you click this link you will be leaving Lilly.com
 

Regulatory Review

  •  
  •  
  •  
  •  
  •  
  •  

Select New Indication or Line Extension (NILEX)

Phase III

  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Phase II

  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Phase I

  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Pipeline Disclaimer
The information included on this site reflects Eli Lilly and Company's clinical development pipeline and is not intended for promotional purposes. It includes both new molecular entities as well as select new indications or line extensions of currently-approved products, that are in clinical development. For competitive reasons, some pipeline molecules are not identified; in those instances, only the therapeutic area in which the molecule is being evaluated is listed. There are significant risks and uncertainties in pharmaceutical research and development. Scientific and regulatory hurdles may cause pipeline molecules to be discontinued, delayed or fail to reach the market. There can be no guarantee that pipeline molecules will receive regulatory approval or that they will prove to be commercially successful. Information is current as of July 15, 2012. Lilly assumes no duty to update this information.
New Molecule
Molecule That Achieved Milestone
Nonproprietary name granted
Later Phase Indication Terminated
Lost through attrition
* Commercial Collaboration
  • NME
  • Select NILEX